George Kemble
Known title: Executive ChairmanCIK: 0001858176
Associated companies
Transaction History
| SGMT | ▲ Buy | Option Exercise | 326,618 | $2.1M | 8/14/2026 | View on chart |
| SGMT | ▲ Buy | Option Exercise | 24,369 | $155K | 8/14/2026 | View on chart |
| SGMT | ▼ Sell | Open Market | 350,987 | $3.6M | 8/14/2026 | View on chart |
| SGMT | ▲ Buy | Option Exercise | 9,751 | $62K | 8/11/2026 | View on chart |
| SGMT | ▲ Buy | Option Exercise | 10,455 | $66K | 8/11/2026 | View on chart |
| SGMT | ▼ Sell | Open Market | 20,206 | $201K | 8/11/2026 | View on chart |
| SGMT | ▼ Sell | Open Market | 18,844 | $141K | 7/20/2026 | View on chart |
| SGMT | ▼ Sell | Open Market | 37,688 | $290K | 11/20/2025 | View on chart |
| SGMT | ▼ Sell | Open Market | 23,625 | $75K | 7/23/2024 | View on chart |
| SGMT | ▼ Sell | Open Market | 14,062 | $44K | 7/19/2024 | View on chart |
| SGMT | ▲ Buy | Grant | 150,750 | $0 | 11/17/2023 | View on chart |
| SGMT | ▲ Buy | Option Exercise | 5,630 | $4K | 9/7/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Goldman Sachs reinstates Sell rating on SGMT with $7 target
Goldman Sachs has reinstated a Sell rating on Sagimet Biosciences, setting a price target of $7. This move stands in contrast to the average analyst target of $29.60, highlighting a significant divergence in expert opinions. The stock is currently trading near its 52-week low of $4.50, reflecting the bearish sentiment associated with the new rating.
Goldman Sachs reinstates Sell rating on SGMT with $7 target. Goldman Sachs has reinstated a Sell rating on Sagimet Biosciences, setting a price target of $7. This move stands in contrast to the average analyst target of $29.60, highlighting a significant divergence in expert opinions. The stock is currently trading near its 52-week low of $4.50, reflecting the bearish sentiment associated with the new rating.